Drug updated on 4/18/2024
| Dosage Form | Solution (topical ophthalmic; 0.02 mg/mL (0.002%)) |
| Drug Class | Relatively selective prostaglandin E2 (EP2) receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Summary
- Omidenepag isopropyl (Omlonti) is indicated for the reduction of elevated intraocular pressure in individuals with open-angle glaucoma or ocular hypertension.
- The information was derived from a study categorized as a Systematic Review / Meta-Analysis.
- A meta-analysis assessed six studies involving 358 eyes from patients treated with omidenepag isopropyl for at least four weeks. These patients either had glaucoma or normal tension glaucoma.
- There was a significant decrease in intraocular pressure with omidenepag isopropyl monotherapy among these patients. The weighted mean difference after treatment was -4.684, indicating a substantial reduction in elevated IOP levels.
- Subgroups with initial IOP greater than 21 mmHg and those older than 65 years experienced significant reductions in IOP after using this medication, suggesting heightened effectiveness within these groups.
- No differences were observed in the effectiveness of omidenepag isopropyl related to country of origin or dosage frequencies across various demographics and treatment regimens, indicating consistent results regardless of these variables.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Omlonti (omidenepag isopropyl ophthalmic solution) Prescribing Information. | 2022 | Santen Incorporated, Emeryville, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical efficacy of omidenepag isopropyl for primary open-angle glaucoma, normal tension glaucoma, or ocular hypertension: A meta-analysis. | 2023 | Journal Of Ocular Pharmacology and Therapeutics |